Recurrent Mixed Phenotype Acute Leukemia

Explore clinical trials studying Recurrent Mixed Phenotype Acute Leukemia. Study availability and eligibility vary by location and protocol.

9 public trials 4 recruiting studies

Refine in advanced search Browse all conditions

Recurrent Mixed Phenotype Acute Leukemia trial results

Recruiting

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

NCT03128034

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, +34 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT03670966

Conditions: Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, +37 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

NCT03326921

Conditions: Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, +63 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

NCT06928662

Conditions: Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Bone Marrow Diseases, +32 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Completed

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

NCT02135874

Conditions: Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, +16 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

NCT05761171

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +21 more
Locations: Children's Hospital of Alabama Birmingham, Alabama, United States

Arkansas Children's Hospital Little Rock, Arkansas, United States

Kaiser Permanente Downey Medical Center Downey, California, United States

Loma Linda University Medical Center Loma Linda, California, United States

View all 84 locations

View Trial Details

Active, Not Recruiting

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

NCT05146739

Conditions: Acute Myeloid Leukemia Post Cytotoxic Therapy, Bone Marrow Diseases, Hematologic Diseases, +21 more
Locations: Children's Hospital of Alabama Birmingham, Alabama, United States

Children's Hospital Los Angeles Los Angeles, California, United States

Children's Hospital of Orange County Orange, California, United States

UCSF Medical Center-Mission Bay San Francisco, California, United States

View all 19 locations

View Trial Details

Active, Not Recruiting

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

NCT02879695

Conditions: Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +22 more
Locations: Yale University New Haven, Connecticut, United States

University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States

Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Active, Not Recruiting

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

NCT04872790

Conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Burkitt Lymphoma, +23 more
Locations: OHSU Knight Cancer Institute Portland, Oregon, United States

View Trial Details

Recurrent Mixed Phenotype Acute Leukemia

Recurrent Mixed Phenotype Acute Leukemia trial results

Related conditions